Clinical studies demonstrate that scopolamine, a non-selective muscarinic acetylcholine receptor (mAchR) antagonist, produces rapid therapeutic effects in depressed patients, and preclinical studies report that the actions of scopolamine require glutamate receptor activation and the mechanistic target of rapamycin complex 1 (mTORC1). The present study extends these findings to determine the role of the medial prefrontal cortex (mPFC) and specific muscarinic acetylcholine receptor (M-AchR) subtypes in the actions of scopolamine. The administration of scopolamine increases the activity marker Fos in the mPFC, including the infralimbic (IL) and prelimbic (PrL) subregions. Microinfusions of scopolamine into either the IL or the PrL produced significant antidepressant responses in the forced swim test, and neuronal silencing of IL or PrL blocked the antidepressant effects of systemic scopolamine. The results also demonstrate that the systemic administration of a selective M1-AChR antagonist, VU0255035, produced an antidepressant response and stimulated mTORC1 signaling in the PFC, similar to the actions of scopolamine. Finally, we used a chronic unpredictable stress model as a more rigorous test of rapid antidepressant actions and found that a single dose of scopolamine or VU0255035 blocked the anhedonic response caused by CUS, an effect that requires the chronic administration of typical antidepressants. Taken together, these findings indicate that mPFC is a critical mediator of the behavioral actions of scopolamine and identify the M1-AChR as a therapeutic target for the development of novel and selective rapid-acting antidepressants.
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Major depressive disorder (MDD) is a recurring, debilitating illness characterized by depressed mood, diminished self-esteem, decreased motivation, and inability to experience pleasure. Moreover, MDD is one of the leading causes of morbidity and mortality worldwide leading to a significant socioeconomic impact on health care systems (Kessler et al., 2003) . Given the unmet needs in the treatment of this condition, including tolerability, slow onset of action, and low rates of efficacy (Fournier et al., 2010; Papakostas, 2007) , the search for new therapies that can overcome these limitations has been a high priority of drug development programs. Recent clinical findings have provided several novel treatments that address these issues, including the NMDA receptor antagonist ketamine (Berman et al., 2000; Zarate et al., 2006) and the non-selective muscarinic acetylcholine receptor (M-AChR) antagonist scopolamine (Drevets and Furey, 2010; Furey and Drevets, 2006) , both of which produce rapid antidepressant actions in depressed patients, including patients considered treatment resistant (i.e., have failed to respond to two or more typical antidepressant agents).
Recent mechanistic studies in rodent models have demonstrated similarities in the downstream cellular actions underlying the rapid antidepressant effects of ketamine and scopolamine (Duman and Aghajanian, 2012; Li et al., 2010 Li et al., , 2011 Voleti et al., 2013) . We have reported that a single dose of scopolamine, like ketamine, rapidly increases the mechanistic target of rapamycin complex 1 (mTORC1) signaling in the medial prefrontal cortex (mPFC), and that the antidepressant behavioral actions of scopolamine are blocked by infusion of rapamycin, a selective inhibitor of mTORC1 (Voleti et al., 2013) . These studies also show that the behavioral actions of scopolamine, like ketamine, are blocked by pretreatment with a glutamate AMPA receptor antagonist, consistent with evidence that scopolamine and ketamine cause a rapid, transient burst of glutamate in the mPFC (Li et al., 2010; Moghaddam et al., 1997; Voleti et al., 2013) . This burst of glutamate is thought to occur via blockade of muscarinic or NMDA receptors by scopolamine or ketamine, respectively, on GABA interneurons, resulting Neurobiology of Disease 82 (2015) 254-261 
